Additionally, subgroup analyses have provided insights into its effectiveness in patients with advanced CKD, comorbid atherosclerotic CV disease, and in those receiving concomitant therapies such as diuretics and GLP-1 RAs [7]. Here, GLP1R is linked to chronic kidney disease.